AAPL 222.73 -0.4559% MSFT 391.955 -0.8111% NVDA 113.445 -6.003% GOOGL 166.905 -2.1429% GOOG 169.12 -2.124% AMZN 202.04 -1.7841% META 610.7313 -2.4874% AVGO 178.775 -5.0382% LLY 835.66 -1.9581% TSLA 270.5301 -6.1116% TSM 172.12 -4.8535% V 344.51 -0.0319% JPM 251.71 0.231% UNH 517.57 0.8063% NVO 72.16 -1.9565% WMT 84.78 0.0236% LVMUY 128.17 -0.7588% XOM 118.245 1.4195% LVMHF 638.0 -1.6131% MA 548.525 0.6172%
Last update at 2025-03-26T16:51:00Z
Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
Wed 19 Mar 25, 01:35 PMIs Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds?
Wed 19 Mar 25, 12:05 AMStrength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength?
Mon 17 Mar 25, 01:51 PMDown -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
Mon 17 Mar 25, 01:35 PMBiotech Alert: Searches spiking for these stocks today
Fri 14 Mar 25, 04:15 PMThe Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
Fri 14 Mar 25, 02:38 PMPharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
Thu 13 Mar 25, 05:05 PMArvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?
Thu 13 Mar 25, 02:52 PMARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study
Wed 12 Mar 25, 01:39 PMArvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
Tue 11 Mar 25, 10:45 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -251.00000M | -191.00000M | -119.33206M | -70.29223M | -41.48047M |
| Minority interest | - | - | - | - | - |
| Net income | -271.90000M | -183.20000M | -111.78671M | -62.13204M | -41.48047M |
| Selling general administrative | 79.60M | 61.60M | 38.30M | 27.31M | 12.93M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 131.40M | 46.70M | 21.80M | 42.98M | 14.32M |
| Reconciled depreciation | 8.20M | 6.00M | 4.02M | 2.25M | 0.71M |
| Ebit | -271.40000M | -201.30000M | -128.88198M | -53.77742M | -44.50808M |
| Ebitda | -263.20000M | -195.30000M | -124.85748M | -51.52451M | -43.80208M |
| Depreciation and amortization | 8.20M | 6.00M | 4.02M | 2.25M | 0.71M |
| Non operating income net other | 1.60M | 4.40M | 5.59M | -18.68214M | 2.38M |
| Operating income | -263.20000M | -195.30000M | -124.85748M | -51.52451M | -43.80208M |
| Other operating expenses | 394.60M | 242.00M | 146.66M | 94.50M | 58.13M |
| Interest expense | 12.00M | 0.10M | 0.07M | 0.09M | 0.06M |
| Tax provision | 20.90M | - | - | - | - |
| Interest income | 12.20M | 1.90M | 3.59M | 4.56M | 2.47M |
| Net interest income | 12.20M | 1.80M | 3.52M | 4.47M | 2.41M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 20.90M | -7.80000M | -7.54536M | -8.16019M | 2.38M |
| Total revenue | 131.40M | 46.70M | 21.80M | 42.98M | 14.32M |
| Total operating expenses | 394.60M | 242.00M | 146.66M | 94.50M | 58.13M |
| Cost of revenue | - | - | - | - | 0.00000M |
| Total other income expense net | 12.20M | 4.30M | 5.53M | -18.76771M | -0.09105M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -282.50000M | -191.00000M | -119.33206M | -70.29223M | -41.48047M |
| Net income applicable to common shares | -282.50000M | -191.00000M | -119.33206M | -70.29223M | -239.84722M |
| Preferred stock and other adjustments | - | - | - | - | 198.37M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1304.60M | 1268.80M | 1581.60M | 717.37M | 301.64M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 6.50M | 21.40M | 19.70M | 6.11M | 3.73M |
| Total liab | 644.60M | 703.90M | 799.90M | 75.11M | 74.96M |
| Total stockholder equity | 660.00M | 564.90M | 781.70M | 642.26M | 226.69M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 74.40M | 69.00M | 23.10M | 18.86M | 7.60M |
| Common stock | 0.10M | 0.10M | - | 0.05M | 0.04M |
| Capital stock | 0.10M | 0.10M | 0.00000M | 0.05M | 0.04M |
| Retained earnings | -1332.70000M | -965.40000M | -682.90000M | -491.88891M | -372.55685M |
| Other liab | - | 405.10M | 534.30M | 22.94M | 38.43M |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | 10.80M | 0.10M | 0.03M | 0.03M |
| Cash | 317.20M | 81.30M | 108.30M | 588.37M | 9.21M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 257.10M | 295.10M | 261.70M | 49.09M | 32.81M |
| Current deferred revenue | 163.00M | 218.60M | 206.20M | 22.15M | 19.98M |
| Net debt | -313.80000M | -75.80000M | -103.30000M | -584.33297M | -4.82305M |
| Short term debt | 2.10M | 1.80M | 1.10M | 0.95M | 0.67M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 3.40M | 5.50M | 5.00M | 4.04M | 4.39M |
| Other stockholder equity | 1995.70M | 1549.40M | 1469.20M | 1133.54M | 599.10M |
| Property plant equipment | - | 13.40M | 16.60M | 12.26M | 10.73M |
| Total current assets | 1280.20M | 1240.20M | 1552.50M | 703.09M | 290.88M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 564.90M | 781.70M | 642.26M | 226.69M |
| Short term investments | 949.30M | 1124.00M | 1394.30M | 100.16M | 271.66M |
| Net receivables | 7.20M | 8.00M | 25.70M | 8.44M | 6.28M |
| Long term debt | 0.80M | 1.00M | 1.00M | 2.00M | 2.00M |
| Inventory | - | 5.50M | 4.50M | - | - |
| Accounts payable | 17.60M | 5.70M | 31.30M | 7.12M | 4.56M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -3.10000M | -19.20000M | -4.60000M | 0.56M | 0.11M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.10M | - | 0.05M | 0.04M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -965.40000M | -682.90000M | -491.88891M | -372.55685M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 10.40M | 10.80M | 12.50M | 0.03M | 0.03M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 24.40M | 28.60M | 29.10M | 14.28M | 10.76M |
| Capital lease obligations | 2.40M | 4.50M | 4.00M | 2.04M | 2.39M |
| Long term debt total | - | 1.00M | 1.00M | 2.00M | 2.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 249.60M | -1308.90000M | 170.70M | -86.85254M | -176.83470M |
| Change to liabilities | 20.20M | 719.20M | 12.85M | 5.21M | 2.46M |
| Total cashflows from investing activities | 242.80M | -1313.60000M | 164.25M | -93.09656M | -179.66536M |
| Net borrowings | - | - | - | -0.16961M | 1.83M |
| Total cash from financing activities | 4.70M | 278.60M | 504.67M | 139.74M | 168.06M |
| Change to operating activities | - | -26.90000M | 6.34M | -2.07020M | -3.11156M |
| Net income | -282.50000M | -191.00000M | -119.33206M | -70.29223M | -41.48047M |
| Change in cash | -26.00000M | -475.60000M | 579.16M | 6.02M | -27.72234M |
| Begin period cash flow | 112.80M | 588.40M | 9.21M | 3.19M | 30.91M |
| End period cash flow | 86.80M | 112.80M | 588.37M | 9.21M | 3.19M |
| Total cash from operating activities | -273.50000M | 559.40M | -89.75693M | -40.62634M | -16.11767M |
| Issuance of capital stock | 0.00000M | 264.60M | 525.64M | 137.69M | 169.58M |
| Depreciation | 8.20M | 6.00M | 4.02M | 2.25M | 0.71M |
| Other cashflows from investing activities | - | - | - | -86.85254M | -176.83470M |
| Dividends paid | - | - | - | -3.42177M | 60.50M |
| Change to inventory | - | -26.90000M | 6.34M | -2.07020M | -3.26156M |
| Change to account receivables | 14.00M | -14.00000M | -1.00000M | 2.78M | 22.22M |
| Sale purchase of stock | 4.70M | 14.00M | -29.23483M | -0.59713M | -3.42359M |
| Other cashflows from financing activities | 242.80M | 14.00M | 8.26M | 6.25M | 117.57M |
| Change to netincome | 75.50M | 65.70M | 29.84M | 20.07M | 11.82M |
| Capital expenditures | 6.80M | 4.70M | 6.45M | 6.24M | 2.83M |
| Change receivables | 17.70M | -17.30000M | -2.16283M | -1.24903M | 21.01M |
| Cash flows other operating | -116.40000M | 668.30M | -15.76795M | 3.90M | -10.89947M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -26.00000M | -475.60000M | 579.16M | 6.02M | -27.72234M |
| Change in working capital | -82.60000M | 678.30M | -5.93968M | 7.17M | 12.57M |
| Stock based compensation | 75.50M | 57.10M | 30.23M | 20.07M | 11.63M |
| Other non cash items | 7.90M | 9.80M | 1.65M | 0.17M | 0.27M |
| Free cash flow | -280.30000M | 554.70M | -96.20447M | -46.87037M | -18.94833M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ARVN Arvinas Inc |
-0.0699 0.86% | 8.06 | - | 17.70 | 10.70 | 3.04 | 4.10 | -1.6185 |
| NVO Novo Nordisk A/S |
-1.44 1.96% | 72.16 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.28 1.75% | 72.07 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-7.84 1.54% | 501.20 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
0.08 0.01% | 634.22 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
5 Science Park, New Haven, CT, United States, 06511
| Name | Title | Year Born |
|---|---|---|
| Dr. John G. Houston Ph.D. | CEO, Pres & Director | 1960 |
| Mr. Sean A. Cassidy CPA, CPA, M.B.A. | CFO & Treasurer | 1970 |
| Dr. Ian Taylor Ph.D. | Chief Scientific Officer | 1962 |
| Dr. Ronald A. Peck | Chief Medical Officer | NA |
| Mr. Jeff Boyle | VP of Investor Relations | NA |
| Mr. Matthew Batters J.D. | Gen. Counsel & Corp. Sec. | 1975 |
| Dr. Randy Teel Ph.D. | Sr. VP of Corp. & Bus. Devel. | 1979 |
| Mr. Steve Weiss | Sr. VP & Chief HR Officer | 1970 |
| Dr. John A. Grosso Ph.D. | Sr. VP of R&D Technical Operations | 1957 |
| Ms. Angela M. Cacace Ph.D. | Sr. VP of Neuroscience & Platform Biology | 1968 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US
AU
UK
CA
NZ
Please wait processing your request...